Barclays Reiterates an 'Overweight' on Regeneron Pharma (REGN); Sticking with VTE Ahead of CATT Data
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $834.04 +0.90%
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
29 Buy, 19 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays reiterates an 'Overweight' on Regeneron Pharma (NASDAQ: REGN), PT increased from $47 to $56.
Barclays analyst says, "We believe that upside potential for REGN has been underestimated and that various scenarios are favorably skewed in favor of brand antI-VEGF therapy...Medicare claims data suggests that Avastin CV safety may be inferior to brand Lucentis and in the event of inferiority of Avastin data on either VA, safety or PRN dosing we would see upside potential to at least $78/share. We estimate base support from the Sanofi (NYSE: SNY) partnered MAb pipeline at $24/share in the unlikely event that VTE doesn't gain approval...Greatest pipeline focus beyond VTE was on PCSK9 mAb REGN727 with single dose 60% LDL reduction and with multi-dose data possible by YE11."
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $42.85 yesterday.
Barclays analyst says, "We believe that upside potential for REGN has been underestimated and that various scenarios are favorably skewed in favor of brand antI-VEGF therapy...Medicare claims data suggests that Avastin CV safety may be inferior to brand Lucentis and in the event of inferiority of Avastin data on either VA, safety or PRN dosing we would see upside potential to at least $78/share. We estimate base support from the Sanofi (NYSE: SNY) partnered MAb pipeline at $24/share in the unlikely event that VTE doesn't gain approval...Greatest pipeline focus beyond VTE was on PCSK9 mAb REGN727 with single dose 60% LDL reduction and with multi-dose data possible by YE11."
For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $42.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
